Silicosis is a serious
occupational disease characterized by lung
fibrosis that is caused by long-term inhalation of
silica-containing fine particles.
Lysophosphatidic acid (LPA) and LPA1/3 plays a role in lung
fibrosis. Until recently, there has been little research investigating the role of LPA and
LPA receptors (LPAR) in
silica-induced development of
pulmonary fibrosis. In this study, we evaluated the hypothesis that LPA and LPA1/3 may play a role in
silicosis pathogenesis using rat
silicosis models induced by intratracheal instillation of
silica, and randomly divided into control,
silica, and
VPC-12249 groups. LPA serum and bronchoalveolar lavage fluid (BALF) levels were quantified by ELISA. α-smooth muscle actin (α-SMA), type I and III
collagen protein expression was quantified by western blotting (WB), and type I and III
collagen mRNAs detected by
reverse transcriptase-polymerase chain reaction (RT-PCR). Lung
hydroxyproline (HYP) levels were detected using alkaline hydrolysis, with
hematoxylin and
eosin (H&E) and
picrosirius red staining used for pathological examination. In vitro experiments showed that LPA stimulated fibroblasts proliferated in a time and dose-dependent manner and promoted expression of α-SMA, and type I and III
collagen. Moreover, LPA serum and BALF levels increased in
silica-instilled rats. In vivo and in vitro experiments revealed that α-SMA expression and
collagen deposition reduced significantly after
VPC-12249 treatment, and histopathological results show
VPC-12249 alleviates
silicosis progression. In conclusion, our findings suggest that LPA promotes the proliferation, transformation, and
collagen synthesis of fibroblasts, and that LPA-LPA1/3 are involved in the development of
silicosis and may serve as novel therapeutic targets for treatment.